OIT3

Summary

OIT3 (oncoprotein induced transcript 3, HGNC:29953) is a protein-coding gene on chromosome 10q22.1, encoding Oncoprotein-induced transcript 3 protein (Q8WWZ8). May be involved in hepatocellular function and development.

This gene was identified due to its downregulation in hepatocarcinomas. The encoded protein may be involved in liver development and function.

Source: NCBI Gene 170392 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 103 total
• MANE Select transcript: NM_152635

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29953
Approved symbol	OIT3
Name	oncoprotein induced transcript 3
Location	10q22.1
Locus type	gene with protein product
Status	Approved
Aliases	LZP, FLJ39116
Ensembl gene	ENSG00000138315
Ensembl biotype	protein_coding
OMIM	609330
Entrez	170392

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 protein_coding

ENST00000334011, ENST00000622652, ENST00000858589, ENST00000858590, ENST00000858591, ENST00000858592, ENST00000858593, ENST00000858594

RefSeq mRNA: 1 — MANE Select: NM_152635 NM_152635

CCDS: CCDS7318

Canonical transcript exons

ENST00000334011 — 9 exons

Exon	Start	End
ENSE00000834450	72911717	72911839
ENSE00001023972	72913308	72913468
ENSE00001170094	72930538	72930637
ENSE00001170104	72924229	72924644
ENSE00001170128	72906596	72906718
ENSE00001170137	72900377	72900484
ENSE00001339835	72898664	72899038
ENSE00001434413	72893739	72893859
ENSE00001459385	72932354	72933036

Expression profiles

Bgee: expression breadth broad, 78 present calls, max score 91.00.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1148 / max 31.9842, expressed in 25 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
105514	0.0438	9
105512	0.0419	19
105513	0.0291	9

Top tissues by expression

223 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
liver	UBERON:0002107	91.00	gold quality
right lobe of liver	UBERON:0001114	87.71	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.82	gold quality
spleen	UBERON:0002106	71.09	gold quality
pancreatic ductal cell	CL:0002079	68.69	silver quality
right atrium auricular region	UBERON:0006631	66.52	gold quality
cardiac atrium	UBERON:0002081	65.61	gold quality
mucosa of transverse colon	UBERON:0004991	62.90	gold quality
adrenal tissue	UBERON:0018303	62.47	gold quality
small intestine Peyer’s patch	UBERON:0003454	61.22	gold quality
small intestine	UBERON:0002108	60.00	gold quality
adult mammalian kidney	UBERON:0000082	58.86	gold quality
duodenum	UBERON:0002114	56.39	gold quality
epithelial cell of pancreas	CL:0000083	55.70	gold quality
cardiac muscle of right atrium	UBERON:0003379	54.92	gold quality
left ventricle myocardium	UBERON:0006566	54.23	gold quality
kidney epithelium	UBERON:0004819	53.93	gold quality
upper arm skin	UBERON:0004263	53.52	gold quality
ileal mucosa	UBERON:0000331	53.46	silver quality
gall bladder	UBERON:0002110	53.10	gold quality
kidney	UBERON:0002113	52.80	gold quality
tibialis anterior	UBERON:0001385	50.95	silver quality
myocardium	UBERON:0002349	50.49	gold quality
vermiform appendix	UBERON:0001154	50.20	gold quality
deltoid	UBERON:0001476	49.53	gold quality
rectum	UBERON:0001052	49.01	gold quality
cerebellar hemisphere	UBERON:0002245	48.91	gold quality
cerebellar cortex	UBERON:0002129	48.90	gold quality
cerebellar vermis	UBERON:0004720	48.63	gold quality
cerebellum	UBERON:0002037	48.42	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-GEOD-130473	yes	2587.28
E-MTAB-7407	yes	1867.06
E-MTAB-10553	yes	1468.07
E-ANND-5	yes	645.57
E-HCAD-9	yes	20.44
E-ANND-3	no	3.72

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): PBX1, TCF3

miRNA regulators (miRDB)

31 targeting OIT3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-4677-5P	99.70	70.09	1940
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-892C-3P	99.65	69.38	1745
HSA-MIR-452-5P	99.65	69.63	1762
HSA-MIR-4676-3P	99.65	69.31	1733
HSA-MIR-20A-3P	99.44	69.10	1575
HSA-MIR-513A-3P	99.39	70.63	3620
HSA-MIR-513C-3P	99.39	70.63	3620
HSA-MIR-32-3P	99.36	68.20	2517
HSA-MIR-2116-5P	99.32	69.34	1273
HSA-MIR-4291	99.20	68.88	2969
HSA-MIR-8065	99.19	70.38	1289
HSA-MIR-3606-3P	99.11	69.84	3254
HSA-MIR-29A-5P	99.08	68.59	1813
HSA-MIR-3938	98.72	66.07	834
HSA-MIR-6883-3P	97.97	67.35	643
HSA-MIR-4678	97.59	68.31	902
HSA-MIR-6834-5P	96.25	64.88	823
HSA-MIR-759	96.16	66.77	873

Literature-anchored findings (GeneRIF, showing 7)

• Liver-specific ZP domain-containing protein (LZP) is a liver-specific protein involved possibly in hepatocellular function and development. (liver-specific ZP domain-containing protein) (PMID:12939600)
• D8C, a novel domain present in LZP, mutates in familial juvenile hyperuricemia. (PMID:15589826)
• The finding that LZP might act as a new partner of THP would provide novel insights into renal functions related to THP and LZP, such as the urothelial permeability barrier and the host defense against the adhesion of pathogens. (PMID:18830570)
• Loss of heterozygosity of OIT3 gene on chromosome 10q is associated with pancreatic cancer. (PMID:25824785)
• rs554643826 (T439S) may have contributed to inheritance of gout in a Chinese family (PMID:32569156)
• OIT3 mediates macrophage polarization and facilitates hepatocellular carcinoma progression. (PMID:35353239)
• Increased OIT3 in macrophages promotes PD-L1 expression and hepatocellular carcinogenesis via NF-kappaB signaling. (PMID:37201744)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	oit3	ENSDARG00000087227
mus_musculus	Oit3	ENSMUSG00000009654
rattus_norvegicus	Oit3	ENSRNOG00000046365

Paralogs (5): TECTB (ENSG00000119913), UMOD (ENSG00000169344), GP2 (ENSG00000169347), ZPLD1 (ENSG00000170044), UMODL1 (ENSG00000177398)

Protein

Protein identifiers

Oncoprotein-induced transcript 3 protein — Q8WWZ8 (reviewed: Q8WWZ8)

Alternative names: Liver-specific zona pellucida domain-containing protein

All UniProt accessions (1): Q8WWZ8

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in hepatocellular function and development.

Subcellular location. Nucleus envelope.

Tissue specificity. Liver-specific. Expressed only in the hepatocytes. Down-regulated in hepatocellular carcinoma (HCC) and HCC cell lines.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8WWZ8-1	1	yes
Q8WWZ8-2	2

RefSeq proteins (1): NP_689848* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000742	EGF	Domain
IPR001507	ZP_dom	Domain
IPR001881	EGF-like_Ca-bd_dom	Domain
IPR018097	EGF_Ca-bd_CS	Conserved_site
IPR042235	ZP-C_dom	Homologous_superfamily
IPR048290	ZP_chr	Domain
IPR055355	ZP-C	Domain
IPR057774	D8C_UMOD/GP2/OIT3-like	Domain

Pfam: PF00100, PF14670, PF23283

UniProt features (21 total): disulfide bond 8, glycosylation site 4, domain 3, splice variant 2, signal peptide 1, chain 1, sequence variant 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WWZ8-F1	79.35	0.33

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (8): 25–124, 51–139, 74–112, 80–144, 105–113, 186–197, 193–206, 208–221

Glycosylation sites (4): 89, 116, 291, 299

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 62 (showing top): GOCC_CELL_SURFACE, GOBP_RENAL_SYSTEM_PROCESS, GOCC_NUCLEAR_ENVELOPE, STAT5A_01, BOCHKIS_FOXA2_TARGETS, CHEN_METABOLIC_SYNDROM_NETWORK, GOCC_ORGANELLE_ENVELOPE, WHITFIELD_CELL_CYCLE_G2_M, GUILLAUMOND_KLF10_TARGETS_DN, RATTENBACHER_BOUND_BY_CELF1, NABA_ECM_GLYCOPROTEINS, ZNF7_TARGET_GENES, MIR452_5P, MIR892C_3P, MIR4676_3P

GO Biological Process (1): renal system process (GO:0003014)

GO Molecular Function (2): calcium ion binding (GO:0005509), protein binding (GO:0005515)

GO Cellular Component (4): obsolete extracellular space (GO:0005615), nuclear envelope (GO:0005635), cell surface (GO:0009986), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
system process	1
metal ion binding	1
binding	1
nucleus	1
endomembrane system	1
organelle envelope	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

730 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OIT3	PLAC8L1	A1L4L8	422
OIT3	STAB2	Q8WWQ8	419
OIT3	FCN2	Q15485	371
OIT3	CLEC4G	Q6UXB4	354
OIT3	TMCO2	Q7Z6W1	349
OIT3	SLC71A2	Q5SR56	335
OIT3	CCDC174	Q6PII3	328
OIT3	LYVE1	Q9Y5Y7	325
OIT3	FCN3	O75636	314
OIT3	ANGPTL6	Q8NI99	301
OIT3	MMRN2	Q9H8L6	297
OIT3	MAP6D1	Q9H9H5	292
OIT3	ENKUR	Q8TC29	292
OIT3	CLEC4F	Q8N1N0	286
OIT3	ACAA2	P42765	264

IntAct

41 interactions, top by confidence:

A	B	Type	Score
OIT3	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
MEOX2	OIT3	psi-mi:“MI:0915”(physical association)	0.560
OIT3	OTX1	psi-mi:“MI:0915”(physical association)	0.560
OIT3	FBXO34	psi-mi:“MI:0915”(physical association)	0.560
OIT3	HOXA1	psi-mi:“MI:0915”(physical association)	0.560
OIT3	CRCT1	psi-mi:“MI:0915”(physical association)	0.560
OIT3	LCE1C	psi-mi:“MI:0915”(physical association)	0.560
OIT3	KRTAP11-1	psi-mi:“MI:0915”(physical association)	0.560
OIT3	LCE1F	psi-mi:“MI:0915”(physical association)	0.560
OIT3	LCE3A	psi-mi:“MI:0915”(physical association)	0.560
OIT3	VAC14	psi-mi:“MI:0915”(physical association)	0.560
ECE1	OIT3	psi-mi:“MI:0915”(physical association)	0.370
TANK	CNOT1	psi-mi:“MI:0914”(association)	0.350
Mecom	ESYT2	psi-mi:“MI:0914”(association)	0.350
OIT3	WNT10B	psi-mi:“MI:0914”(association)	0.350
OIT3	MEOX2	psi-mi:“MI:0915”(physical association)	0.000
OIT3	VAC14	psi-mi:“MI:0915”(physical association)	0.000
OIT3	KRTAP11-1	psi-mi:“MI:0915”(physical association)	0.000
OIT3	LCE1F	psi-mi:“MI:0915”(physical association)	0.000
OIT3	HOXA1	psi-mi:“MI:0915”(physical association)	0.000
OIT3	CRCT1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (65): OIT3 (Two-hybrid), OIT3 (Affinity Capture-MS), OIT3 (Two-hybrid), OIT3 (Two-hybrid), OIT3 (Two-hybrid), CRCT1 (Two-hybrid), FBXO34 (Two-hybrid), KRTAP11-1 (Two-hybrid), LCE3A (Two-hybrid), LCE1C (Two-hybrid), LCE1F (Two-hybrid), NGLY1 (Affinity Capture-MS), CLSTN1 (Affinity Capture-MS), CRLF1 (Affinity Capture-MS), PDIA5 (Affinity Capture-MS)

ESM2 similar proteins: A1A5Y0, F7A4A7, O08523, O55225, O75443, O77780, P59510, P82279, P98089, P98092, Q0V8S9, Q0V8T0, Q0V8T3, Q0V8T4, Q0V8T5, Q0V8T6, Q0V8T7, Q0V8T8, Q0V8T9, Q29RU2, Q3ZCN5, Q5RCW9, Q5RD64, Q60411, Q62635, Q6DFV8, Q6PZE0, Q6V0K7, Q6ZRI0, Q80Z19, Q8CFM6, Q8CIZ8, Q8CJ69, Q8N2E2, Q8N8U9, Q8R4U0, Q8R4V5, Q8R4Y4, Q8VHS2, Q8WWQ8

Diamond homologs: Q29RU2, Q6DFV8, Q6V0K7, Q8N2E2, Q8R4V5, Q8WWZ8, Q9D733, P07911, P19218, P25291, D3ZHH1, Q8K1E3, P55259, O08523, O08524, O75443, P27590, P48733, Q5R5C1, Q862Z3, Q91X17, Q96PL2, Q9YH85

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

103 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	90
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1678 predictions. Top by Δscore:

Variant	Effect	Δscore
10:72899034:TGGTC:T	donor_gain	1.0000
10:72899035:GGTCG:G	donor_gain	1.0000
10:72899036:GTC:G	donor_gain	1.0000
10:72906594:A:AG	acceptor_gain	1.0000
10:72906595:G:GG	acceptor_gain	1.0000
10:72913303:TGCA:T	acceptor_loss	1.0000
10:72913304:GCAGT:G	acceptor_loss	1.0000
10:72913305:CA:C	acceptor_loss	1.0000
10:72913306:A:AC	acceptor_loss	1.0000
10:72913306:A:AG	acceptor_gain	1.0000
10:72913307:G:GA	acceptor_gain	1.0000
10:72913307:GT:G	acceptor_gain	1.0000
10:72913307:GTC:G	acceptor_gain	1.0000
10:72913307:GTCC:G	acceptor_gain	1.0000
10:72913307:GTCCC:G	acceptor_gain	1.0000
10:72924212:ACCCT:A	acceptor_gain	1.0000
10:72924216:T:TA	acceptor_gain	1.0000
10:72930537:GC:G	acceptor_gain	1.0000
10:72930537:GCT:G	acceptor_gain	1.0000
10:72930537:GCTGT:G	acceptor_gain	1.0000
10:72930634:CAAGG:C	donor_loss	1.0000
10:72930635:AAGG:A	donor_loss	1.0000
10:72930636:AGGTG:A	donor_loss	1.0000
10:72930638:G:GG	donor_gain	1.0000
10:72930639:T:A	donor_loss	1.0000
10:72893856:GTGG:G	donor_gain	0.9900
10:72899037:TC:T	donor_gain	0.9900
10:72899039:G:GG	donor_gain	0.9900
10:72900371:CCATA:C	acceptor_loss	0.9900
10:72900372:CATAG:C	acceptor_loss	0.9900

AlphaMissense

3588 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:72924583:T:C	C436R	0.996
10:72924590:C:A	A438D	0.996
10:72911833:T:A	C262S	0.995
10:72911834:G:C	C262S	0.995
10:72898779:G:C	W59C	0.994
10:72898779:G:T	W59C	0.994
10:72911794:T:C	C249R	0.994
10:72911833:T:C	C262R	0.994
10:72913319:T:A	C268S	0.994
10:72913320:G:C	C268S	0.994
10:72924584:G:A	C436Y	0.994
10:72924585:C:G	C436W	0.994
10:72930618:T:G	F483C	0.994
10:72932369:T:C	C495R	0.994
10:72932371:C:G	C495W	0.994
10:72911794:T:A	C249S	0.993
10:72911795:G:C	C249S	0.993
10:72911834:G:A	C262Y	0.993
10:72913397:T:A	C294S	0.993
10:72913398:G:C	C294S	0.993
10:72924343:T:C	C356R	0.993
10:72932370:G:A	C495Y	0.993
10:72911749:T:A	C234S	0.992
10:72911750:G:C	C234S	0.992
10:72911835:C:G	C262W	0.992
10:72924344:G:A	C356Y	0.992
10:72924583:T:A	C436S	0.992
10:72924584:G:C	C436S	0.992
10:72906673:T:A	C208S	0.991
10:72906674:G:C	C208S	0.991

dbSNP variants (sampled 300 via entrez): RS1000054734 (10:72913081 C>A,T), RS1000089075 (10:72932000 C>T), RS1000212614 (10:72928034 A>G), RS1000314997 (10:72905955 T>C), RS1000380584 (10:72892118 A>T), RS1000550383 (10:72926493 C>T), RS1000575958 (10:72919629 C>G), RS1000668158 (10:72912898 G>A), RS1000683781 (10:72932977 C>T), RS1000686730 (10:72905668 A>G), RS1000803524 (10:72912567 G>A), RS1000813125 (10:72926206 C>T), RS1000858747 (10:72893763 G>A), RS1000919285 (10:72894099 A>G), RS1001059509 (10:72920148 C>T)

Disease associations

OMIM: gene MIM:609330 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST006004_2	Low density lipoprotein cholesterol levels	9.000000e-15
GCST006034_23	Total cholesterol levels	3.000000e-09
GCST010002_290	Refractive error	2.000000e-17
GCST010866_143	Coronary artery disease	4.000000e-11
GCST011346_60	Total cholesterol levels	7.000000e-09
GCST011347_36	Low density lipoprotein cholesterol levels	7.000000e-12

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004574	total cholesterol measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, increases methylation, decreases expression, decreases reaction, increases abundance	2
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	2
aristolochic acid I	increases expression	1
fluorene-9-bisphenol	increases expression	1
ginger extract	increases abundance, decreases expression, decreases reaction	1
CGP 52608	affects binding, increases reaction	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	decreases expression	1
Atrazine	increases expression	1
Oils, Volatile	increases abundance, decreases expression, decreases reaction	1
Plant Extracts	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Triclosan	decreases expression	1
Valproic Acid	affects expression	1
Cadmium Chloride	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer